Boston Scientific Target of Unusually Large Options Trading (NYSE:BSX)

Boston Scientific Corporation (NYSE:BSX) was the target of unusually large options trading on Monday. Stock traders bought 23,040 put options on the stock. This is an increase of 27% compared to the typical daily volume of 18,181 put options.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Wells Fargo & Company dropped their price target on shares of Boston Scientific from $125.00 to $94.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. UBS Group dropped their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating on the stock in a research note on Thursday, February 5th. Needham & Company LLC cut their price target on shares of Boston Scientific from $121.00 to $97.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Finally, Citigroup decreased their price objective on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $108.36.

Insider Buying and Selling

In other news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

Several large investors have recently modified their holdings of BSX. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% during the fourth quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. Andra AP fonden bought a new position in shares of Boston Scientific in the second quarter worth about $41,000. Savant Capital LLC lifted its position in shares of Boston Scientific by 4.1% during the 2nd quarter. Savant Capital LLC now owns 21,236 shares of the medical equipment provider’s stock valued at $2,281,000 after buying an additional 834 shares in the last quarter. KCM Investment Advisors LLC grew its stake in shares of Boston Scientific by 9.7% during the 2nd quarter. KCM Investment Advisors LLC now owns 9,930 shares of the medical equipment provider’s stock valued at $1,067,000 after acquiring an additional 876 shares during the period. Finally, AE Wealth Management LLC increased its holdings in Boston Scientific by 6.9% in the 2nd quarter. AE Wealth Management LLC now owns 19,866 shares of the medical equipment provider’s stock worth $2,134,000 after acquiring an additional 1,280 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $0.26 during trading on Monday, reaching $71.61. 4,887,907 shares of the company traded hands, compared to its average volume of 15,976,254. The firm has a 50 day simple moving average of $85.03 and a 200-day simple moving average of $94.47. Boston Scientific has a 52-week low of $69.52 and a 52-week high of $109.50. The stock has a market capitalization of $106.26 billion, a PE ratio of 36.91, a P/E/G ratio of 1.00 and a beta of 0.69. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. During the same quarter in the prior year, the firm earned $0.70 earnings per share. The firm’s revenue for the quarter was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts anticipate that Boston Scientific will post 2.85 earnings per share for the current year.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.